So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair ... with the scientific team ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Regular meetings with company management allow the team to ... for roughly 10% of the strategy’s assets. The team remains bullish on Eli Lilly's leadership in the weight-loss market and believes ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

From Oct. 11 through Nov. 6, shares of Eli Lilly fell 16.7%, largely in response to third-quarter results that missed Wall Street expectations. Management also lowered the midpoint of its 2024 earning ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Polen Global Growth Fund initiated a new position in Oracle and did not eliminate any positions. Volatility re-emerged in the ...

Our team is now focused on the successful execution of our Phase ... and further support the potential for deucrictibant to become a preferred therapy for the management of HAE. Long-term prophylaxis ...

Four leaders from U.S.-based healthcare organizations were featured in Fortune's "100 Most Powerful People in Business" list, released Nov. 12. Fortune editors scored candidates based on metrics ...